Daré Bioscience (NASDAQ:DARE) Share Price Crosses Below Two Hundred Day Moving Average – Time to Sell?

Daré Bioscience, Inc. (NASDAQ:DARE) passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $3.18 and traded as low as $2.88. Daré Bioscience shares last traded at $2.88, with a volume of 13,347 shares.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Daré Bioscience in a research note on Tuesday, April 1st.

Daré Bioscience Trading Down 0.3%

The firm has a market capitalization of $25.49 million, a price-to-earnings ratio of -4.88 and a beta of 1.20. The stock has a fifty day moving average of $2.92 and a 200-day moving average of $3.18.

Daré Bioscience (NASDAQ:DARE) last announced its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.50) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.13. The company had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.60 million. During the same period in the prior year, the firm earned ($0.84) EPS. As a group, equities research analysts forecast that Daré Bioscience, Inc. will post -0.49 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Daré Bioscience

Several institutional investors and hedge funds have recently added to or reduced their stakes in DARE. AMH Equity Ltd boosted its holdings in shares of Daré Bioscience by 9.5% in the 1st quarter. AMH Equity Ltd now owns 164,302 shares of the biotechnology company’s stock worth $475,000 after acquiring an additional 14,302 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Daré Bioscience by 4.0% in the 4th quarter. Geode Capital Management LLC now owns 92,653 shares of the biotechnology company’s stock worth $289,000 after acquiring an additional 3,593 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Daré Bioscience by 6.7% in the 4th quarter. Renaissance Technologies LLC now owns 68,695 shares of the biotechnology company’s stock worth $214,000 after acquiring an additional 4,300 shares in the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of Daré Bioscience in the 4th quarter worth approximately $52,000. 6.70% of the stock is currently owned by institutional investors.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.